Clinical Trial Update: A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases [Phase 2]

View source ↗

Summary

Completed Phase 2 clinical trial of Emricasan (IDN-6556) in subjects with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-07-21